Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep activates interferon (IFN) signalling

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 25, 2022 1:29pm

130 Views

Post# 35191569

RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signalling

Interesting 2014 paper - which supports ONCY's pelareorep clinical development as a immune molecule platform technology and its mechanism of action (MOA) in "priming" the TME in advance of the addition of PD_(L)1 immune checkpoint inhibitors.Skip Nav Destination

<< Previous

Bullboard Posts

Next >>

High Tide adds two stores to undervalued cannabis retail network